This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Amgen Dirección

Dirección controles de criterios 3/4

El CEO de Amgen es Bob Bradway , nombrado en May 2010, tiene una permanencia de 14.25 años. compensación anual total es $22.64M, compuesta por 7.9% salario y 92.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.12% de las acciones de la empresa, por valor de €180.03M. La antigüedad media del equipo directivo y de la junta directiva es de 4.9 años y 7.7 años, respectivamente.

Información clave

Bob Bradway

Chief Executive Officer (CEO)

US$22.6m

Compensación total

Porcentaje del salario del CEO	7.9%
Permanencia del CEO	14.3yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4.9yrs
Promedio de permanencia en la Junta Directiva	7.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bob Bradway en comparación con los beneficios de Amgen?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	US$3b
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$23m	US$2m	US$7b
Sep 30 2023	n/a	n/a	US$8b
Jun 30 2023	n/a	n/a	US$8b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$21m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$7b
Jun 30 2022	n/a	n/a	US$7b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$7b
Dec 31 2020	US$20m	US$2m	US$7b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$20m	US$2m	US$8b
Sep 30 2019	n/a	n/a	US$8b
Jun 30 2019	n/a	n/a	US$8b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$19m	US$2m	US$8b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$17m	US$2m	US$2b

Compensación vs. Mercado: La compensación total de Bob($USD22.64M) está por encima de la media de empresas de tamaño similar en el mercado BG ($USD4.40M).

Compensación vs. Ingresos: La compensación de Bob ha sido consistente con los resultados de la empresa en el último año.

CEO

Bob Bradway (61 yo)

14.3yrs

Permanencia

US$22,643,650

Compensación

Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Bradway	Chairman	14.3yrs	US$22.64m	0.12% € 180.0m
Peter Griffith	Executive VP & CFO	4.6yrs	US$7.57m	0.0046% € 7.1m
Esteban Santos	Executive Vice President of Operations	8.1yrs	US$7.21m	0.011% € 17.6m
David Reese	Executive VP & CTO	less than a year	US$7.90m	0.0094% € 14.5m
Murdo Gordon	Executive Vice President of Global Commercial Operations	5.9yrs	US$8.24m	0.0075% € 11.5m
Matthew Busch	Chief Accounting Officer & VP of Finance	less than a year	sin datos	0.00056% € 860.5k
Mike Zahigian	Senior VP & Chief Information Officer	5.6yrs	sin datos	sin datos
James Bradner	Executive VP of Research & Development and Chief Scientific Officer	less than a year	sin datos	sin datos
Justin Claeys	Vice President of Investor Relations	no data	sin datos	sin datos
Jonathan Graham	Executive VP	9.1yrs	US$7.24m	0.0047% € 7.2m
Nancy Grygiel	Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer	4.6yrs	sin datos	0.0013% € 2.0m
Susan Sweeney	Senior Vice President of Global Marketing	4.9yrs	sin datos	sin datos

4.9yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AM1 se considera experimentado (4.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Bradway	Chairman	12.8yrs	US$22.64m	0.12% € 180.0m
Robert Eckert	Lead Independent Director	11.7yrs	US$419.92k	0.0013% € 2.0m
David Baltimore	Co-Chair of Scientific Advisory Board	no data	US$292.01k	sin datos
Charles Sigal	Co-Chair of the Scientific Advisory Board	no data	sin datos	sin datos
Amy Miles	Independent Director	4.1yrs	US$359.92k	0.000080% € 122.9k
Charles Holley	Independent Director	7.5yrs	US$369.92k	0.00023% € 353.4k
Greg Garland	Independent Director	10.8yrs	US$379.92k	0.0023% € 3.5m
Ellen Kullman	Independent Director	7.8yrs	US$360.29k	0.000080% € 122.9k
Brian Druker	Independent Director	6.3yrs	US$359.92k	0.00015% € 230.5k
Tyler Jacks	Independent Director	12.3yrs	US$339.92k	0.00051% € 783.7k
Wanda Austin	Independent Director	6.7yrs	US$359.92k	0.0012% € 1.9m
S. Ishrak	Independent Director	3.1yrs	US$366.47k	0.00017% € 261.2k

7.7yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de AM1 se considera experimentada (7.7 años de antigüedad promedio).

This company listing is no longer active

Amgen Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Inc. Announces Executive Changes

Executive VP recently sold €2.5m worth of stock

Insider recently sold €2.3m worth of stock

Amgen Inc. Announces Management Changes

Recent updates

Second quarter 2024 earnings released: EPS: US$1.39 (vs US$2.58 in 2Q 2023)

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q2, 2024 Results on Aug 06, 2024

Insufficient new directors

Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto

Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)

FDA Approves Amgen's IMDELLTRA™? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer

New minor risk - Profit margin trend

First quarter 2024 earnings released: US$0.21 loss per share (vs US$5.32 profit in 1Q 2023)

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q1, 2024 Results on May 02, 2024

Amgen to Submits Marketing Authorization Application to the European Medicines Agency

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Presents New Research on Otezla (Apremilast) at AAD 2024

Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: US$12.56 (vs US$12.18 in FY 2022)

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q4, 2023 Results on Feb 06, 2024

Amgen Provides Regulatory Update on Status of LUMAKRAS (Sotorasib)

Amgen Inc. Announces Executive Changes

Executive VP recently sold €2.5m worth of stock

Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023

Amgen Inc. Presents New Data That Show Blood Pressure Decides for Results Treated with Krystexxa (PegLOTICase)

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$3.23 (vs US$4.01 in 3Q 2022)

Amgen Inc. to Report Q3, 2023 Results on Oct 31, 2023

Amgen Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 8, 2023

Amgen Presents New LUMAKRAS (Sotorasib) Plus Vectibix (Panitumumab) Data in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Amgen Inc. to Present New Research from Oncolfolio and Pipeline At ESMO2023

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Presents New Lumakras® (Sotorasib) Plus Chemotherapy Data in First-Line Kras G12c Nsclc At Wclc

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen Presents Phase 2 OLPASIRan Data at ESC 2023

Amgen Announces to Discuss Application for LUMAKRAS (Sotorasib) for Treatment of KRAS G12C-Positive NSCLC at FDA Advisory Committee Meeting

Insider recently sold €2.3m worth of stock

Amgen Inc. Announces Management Changes

Second quarter 2023 earnings released: EPS: US$2.58 (vs US$2.46 in 2Q 2022)

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Amgen Inc. to Report Q2, 2023 Results on Aug 03, 2023

Amgen Inc. Announces U.S. Food and Drug Administration Approves Supplemental Biologics License Application for BLINCYTO

Amgen Presents New Lumakras® (Sotorasib) Codebreak 200 CNS Data At Asco 2023

Amgen Presents New Scientific and Clinical Research Across its Diverse Oncology Portfolio and Pipeline at ASCO 2023

Amgen Presents New Research on Otezla® (Apremilast) in Psoriatic Arthritis At Eular 2023

Amgen Inc. Announces New Data from A Real-World Study of Nearly Half of Million Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

First quarter 2023 earnings released: EPS: US$5.32 (vs US$2.69 in 1Q 2022)

AstraZeneca and Amgen Announce Approval of TEZSPIRE® (tezepelumab-ekko) in the US

Full year 2022 earnings released: EPS: US$12.18 (vs US$10.34 in FY 2021)

Amgen Inc. to Report Q4, 2022 Results on Jan 31, 2023

Amgen Announces ECOG-ACRIN Cancer Research Group Results

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad